JP2002508670A - 細胞型特異的レポーターである蛍光タンパク質 - Google Patents
細胞型特異的レポーターである蛍光タンパク質Info
- Publication number
- JP2002508670A JP2002508670A JP50631699A JP50631699A JP2002508670A JP 2002508670 A JP2002508670 A JP 2002508670A JP 50631699 A JP50631699 A JP 50631699A JP 50631699 A JP50631699 A JP 50631699A JP 2002508670 A JP2002508670 A JP 2002508670A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- promoter
- human
- gfp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091006047 fluorescent proteins Proteins 0.000 title claims abstract description 21
- 102000034287 fluorescent proteins Human genes 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000004113 cell culture Methods 0.000 claims abstract description 22
- 108020004414 DNA Proteins 0.000 claims abstract description 18
- 238000011161 development Methods 0.000 claims abstract description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 13
- 230000002110 toxicologic effect Effects 0.000 claims abstract description 10
- 231100000027 toxicology Toxicity 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 8
- 230000001419 dependent effect Effects 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 135
- 230000014509 gene expression Effects 0.000 claims description 29
- 102000007469 Actins Human genes 0.000 claims description 18
- 108010085238 Actins Proteins 0.000 claims description 18
- 210000002064 heart cell Anatomy 0.000 claims description 16
- 238000004520 electroporation Methods 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 231100000065 noncytotoxic Toxicity 0.000 claims description 11
- 230000002020 noncytotoxic effect Effects 0.000 claims description 11
- 239000003623 enhancer Substances 0.000 claims description 7
- 239000005090 green fluorescent protein Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 210000002459 blastocyst Anatomy 0.000 claims description 6
- 238000000691 measurement method Methods 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 5
- 210000001612 chondrocyte Anatomy 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000004498 neuroglial cell Anatomy 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 3
- 101150114527 Nkx2-5 gene Proteins 0.000 claims description 2
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 claims description 2
- 210000002257 embryonic structure Anatomy 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 108700019146 Transgenes Proteins 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 108010054624 red fluorescent protein Proteins 0.000 claims 1
- 230000018109 developmental process Effects 0.000 abstract description 15
- 230000009261 transgenic effect Effects 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000023715 cellular developmental process Effects 0.000 abstract 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 22
- 230000004069 differentiation Effects 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 210000002242 embryoid body Anatomy 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000001020 rhythmical effect Effects 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 238000010187 selection method Methods 0.000 description 4
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100036639 Myosin-11 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.非細胞損傷性蛍光タンパク質をコードするDNA配列;ならびに 当該DNA配列に操作しやすいように連結した細胞および/または発生依存 プロモーター を含むDNA構成を安定してトランスフェクトしたヒト以外の哺乳類の胚幹(E S)細胞。 2.当該ES細胞を齧歯、特にマウスから得る請求項1に記載のES細胞。 3.当該非細胞損傷性蛍光タンパク質がグリーン・フルオレセント・プロテイン (GFP)、レッド・フルオレセント・プロテインおよびブルー・フルオレセント ・プロテイン、特にGFPから選択される請求項1または2に記載のES細胞。 4.当該プロモーターが心臓細胞、ニューロン、グリア細胞、造血性細胞、内皮 細胞、平滑筋細胞、骨格筋細胞、軟骨細胞、繊維芽細胞または上皮細胞に特異的 なプロモーター、特に心臓細胞に特異的なプロモーターである請求項1から3の 何れかに記載のES細胞。 5.当該プロモーターがNkx-2.5、ヒトα-アクチンおよびMLC-2Vプ ロモーターから選択される、特に心臓特異的ヒトα-アクチンプロモーターであ る請求項5に記載のES細胞。 6.当該DNA構成が機能性DNA配列、特にエンハンサーおよび選択配列を更 に含む請求項1から5の何れかに記載のES細胞。 7.ヒト以外の哺乳類の出発ES細胞に、請求項1および3から6に記載のDN A構成を導入すること、 安定してトランスフェクトされたES細胞をスクリーニングすること を含む請求項1から6の何れかに記載のES細胞を調製する方法。 8.当該導入をエレクトロポレーションにより実施する請求項7に記載の方法。 9.請求項1および3から6の何れかに記載のDNA構成。 10.プラスミドpCX(α-act)GFP-Neo(DSM11633)であるこ とを特徴する請求項9に記載のDNA構成。 11.インビトロで請求項1から6の何れかに記載のES細胞を培養することに より得ることが出来る、非細胞損傷性蛍光タンパク質の細胞型特異的発現を示す 細胞培養。 12.細胞が集塊型である請求項11に記載の細胞培養。 13.蛍光測定方法を用いた請求項11または12に記載の細胞培養における物 質の効果の検査を含む物質の毒理学的検査用の方法。 14.請求項1から6の何れかに記載のES細胞をヒト以外の哺乳類の胚盤胞に 注入すること、および 代理母に胚盤胞を移すこと を含む非細胞損傷性蛍光タンパク質の細胞型特異的発現を示すヒト以外のトラン スジェニック哺乳類をつくる方法。 15.請求項14に記載の方法により得ることが出来るヒト以外のトランスジェ ニック哺乳類。 16.蛍光測定方法を用いインビトロで請求項15に記載のヒト以外の哺乳類の 対応する標識細胞の検査を含むヒト以外の哺乳類の細胞の発生段階を検査する方 法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19727962.7 | 1997-07-02 | ||
DE19727962A DE19727962A1 (de) | 1997-07-02 | 1997-07-02 | Fluoreszierende Proteine als zelltypspezifische Reporter |
PCT/EP1998/003988 WO1999001552A1 (de) | 1997-07-02 | 1998-06-30 | Fluoreszierende proteine als zelltypspezifische reporter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002508670A true JP2002508670A (ja) | 2002-03-19 |
JP3956154B2 JP3956154B2 (ja) | 2007-08-08 |
Family
ID=7834239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50631699A Expired - Lifetime JP3956154B2 (ja) | 1997-07-02 | 1998-06-30 | 細胞型特異的レポーターである蛍光タンパク質 |
Country Status (9)
Country | Link |
---|---|
US (2) | US7105344B2 (ja) |
EP (1) | EP1002080B9 (ja) |
JP (1) | JP3956154B2 (ja) |
AT (1) | ATE234357T1 (ja) |
DE (2) | DE19727962A1 (ja) |
DK (1) | DK1002080T3 (ja) |
ES (1) | ES2191324T3 (ja) |
PT (1) | PT1002080E (ja) |
WO (1) | WO1999001552A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011118655A1 (ja) * | 2010-03-23 | 2011-09-29 | オリンパス株式会社 | 幹細胞の分化状態をモニタリングする方法 |
US8318488B1 (en) | 2004-05-11 | 2012-11-27 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
JP2014176364A (ja) * | 2013-03-15 | 2014-09-25 | Olympus Corp | 幹細胞の解析方法 |
US9945840B2 (en) | 2004-04-07 | 2018-04-17 | Axiogenesis Ag | Non-invasive, in vitro functional tissue assay systems |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19727962A1 (de) * | 1997-07-02 | 1999-01-14 | Juergen Hescheler | Fluoreszierende Proteine als zelltypspezifische Reporter |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
AU1603701A (en) * | 1999-11-19 | 2001-05-30 | Cold Spring Harbor Laboratory | Transgenic mice expressing fluorescent protein under the control of the nestin promoter |
US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
GB0014009D0 (en) * | 2000-06-08 | 2000-08-02 | Devgen Nv | Compound screens relating to insulin deficiency or insulin resistance |
US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
DE10136702B4 (de) * | 2000-12-27 | 2004-04-22 | Axiogenesis Ag | System zur zell- und entwicklungsspezifischen Selektion differenzierender embryonaler Stammzellen, adulter Stammzellen und embryonaler Keimbahnzellen |
IL156410A0 (en) * | 2000-12-27 | 2004-01-04 | Axiogenesis Ag | System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
CA2441571A1 (en) * | 2001-03-20 | 2002-09-26 | University Of Virginia Patent Foundation | Methods for identifying and purifying smooth muscle progenitor cells |
US7611852B2 (en) * | 2002-07-26 | 2009-11-03 | Wisconsin Alumni Research Foundation | Functional cardiomyocytes from human embryonic stem cells |
WO2004104184A1 (ja) * | 2003-05-20 | 2004-12-02 | Riken | 内胚葉系幹細胞の調製 |
EP3184629A1 (en) * | 2003-06-20 | 2017-06-28 | Axiogenesis Ag | Drug discovery based on in vitro generated tissue |
WO2005005621A2 (en) * | 2003-07-08 | 2005-01-20 | Axiogenesis Ag | NOVEL METHOD FOR THE PREPARATION OF EMBRYOID BODIES (EBs) AND USES THEREOF |
US20090328243A1 (en) * | 2003-07-08 | 2009-12-31 | Andreas Ehlich | Secreted proteins as markers for cell differentiation |
US20060292694A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Reporter hepatocytes and other cells for drug screening and toxicity testing |
US20060292695A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells |
CA2613529A1 (en) * | 2005-06-22 | 2007-01-04 | Geron Corporation | Reporter hepatocytes and other cells for drug screening and toxicity testing |
ITPI20100085A1 (it) | 2010-07-07 | 2012-01-08 | Sara Migliarini | Procedimento per l'ingegnerizzazione genetica di cellule staminali che attivano un tracciante fluorescente vitale in seguito al differenziamento in vitro delle cellule stesse verso il tipo cellulare specifico dei neuroni serotoninergici. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0981633A2 (en) * | 1997-02-13 | 2000-03-01 | Memorial Sloan-Kettering Cancer Center | Hybrid molecules for optically detecting changes in cellular microenvironments |
DE19727962A1 (de) * | 1997-07-02 | 1999-01-14 | Juergen Hescheler | Fluoreszierende Proteine als zelltypspezifische Reporter |
IL156410A0 (en) * | 2000-12-27 | 2004-01-04 | Axiogenesis Ag | System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
EP3184629A1 (en) * | 2003-06-20 | 2017-06-28 | Axiogenesis Ag | Drug discovery based on in vitro generated tissue |
WO2005005621A2 (en) * | 2003-07-08 | 2005-01-20 | Axiogenesis Ag | NOVEL METHOD FOR THE PREPARATION OF EMBRYOID BODIES (EBs) AND USES THEREOF |
-
1997
- 1997-07-02 DE DE19727962A patent/DE19727962A1/de not_active Ceased
-
1998
- 1998-06-30 ES ES98940092T patent/ES2191324T3/es not_active Expired - Lifetime
- 1998-06-30 EP EP98940092A patent/EP1002080B9/de not_active Expired - Lifetime
- 1998-06-30 DK DK98940092T patent/DK1002080T3/da active
- 1998-06-30 JP JP50631699A patent/JP3956154B2/ja not_active Expired - Lifetime
- 1998-06-30 AT AT98940092T patent/ATE234357T1/de active
- 1998-06-30 DE DE59807479T patent/DE59807479D1/de not_active Expired - Lifetime
- 1998-06-30 PT PT98940092T patent/PT1002080E/pt unknown
- 1998-06-30 WO PCT/EP1998/003988 patent/WO1999001552A1/de active IP Right Grant
-
2002
- 2002-02-28 US US10/084,960 patent/US7105344B2/en not_active Expired - Lifetime
-
2005
- 2005-12-05 US US11/293,932 patent/US20060168665A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9945840B2 (en) | 2004-04-07 | 2018-04-17 | Axiogenesis Ag | Non-invasive, in vitro functional tissue assay systems |
US8318488B1 (en) | 2004-05-11 | 2012-11-27 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
US9726662B2 (en) | 2004-05-11 | 2017-08-08 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
WO2011118655A1 (ja) * | 2010-03-23 | 2011-09-29 | オリンパス株式会社 | 幹細胞の分化状態をモニタリングする方法 |
JP5860805B2 (ja) * | 2010-03-23 | 2016-02-16 | オリンパス株式会社 | 幹細胞の分化状態をモニタリングする方法 |
JP2014176364A (ja) * | 2013-03-15 | 2014-09-25 | Olympus Corp | 幹細胞の解析方法 |
Also Published As
Publication number | Publication date |
---|---|
US20060168665A1 (en) | 2006-07-27 |
ES2191324T3 (es) | 2003-09-01 |
PT1002080E (pt) | 2003-06-30 |
DK1002080T3 (da) | 2003-05-26 |
DE59807479D1 (de) | 2003-04-17 |
EP1002080B1 (de) | 2003-03-12 |
EP1002080A1 (de) | 2000-05-24 |
WO1999001552A1 (de) | 1999-01-14 |
US20020092035A1 (en) | 2002-07-11 |
DE19727962A1 (de) | 1999-01-14 |
EP1002080B9 (de) | 2004-08-11 |
ATE234357T1 (de) | 2003-03-15 |
US7105344B2 (en) | 2006-09-12 |
JP3956154B2 (ja) | 2007-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3956154B2 (ja) | 細胞型特異的レポーターである蛍光タンパク質 | |
US7220584B2 (en) | Method of making embryoid bodies from primate embryonic stem cells | |
JP4891884B2 (ja) | 分化中の胚幹細胞、成体幹細胞および胚生殖系細胞を細胞特異的および成長特異的に選択するためのシステム | |
Zweigerdt et al. | Generation of confluent cardiomyocyte monolayers derived from embryonic stem cells in suspension: a cell source for new therapies and screening strategies | |
Klug et al. | DNA synthesis and multinucleation in embryonic stem cell-derived cardiomyocytes | |
US9994822B2 (en) | Cardiomyocyte differentiation | |
US20070161107A1 (en) | Differentiation of human embryonic stem cells to cardiomyocytes | |
US20160320409A1 (en) | Method for identifying and selecting cardiomyocytes | |
JPWO2004104184A1 (ja) | 内胚葉系幹細胞の調製 | |
Moore et al. | A P19Cl6 GFP reporter line to quantify cardiomyocyte differentiation of stem cells. | |
Wobus et al. | Embryonic stem cell-derived cardiac differentiation: modulation of differentiation and “loss-of-function” analysis in vitro | |
Robbins et al. | Embryonic stem cells as a model for cardiogenesis | |
Jakob et al. | [6] Mouse teratocarcinoma cells | |
JP2008141973A (ja) | 心筋細胞の培養増殖法 | |
WO2006021459A1 (en) | Compositions and methods for modulating cell differentiation | |
Arnhold et al. | GFP labelled ES cell derived neural precursor cells differentiate into Thy-1 positive neurons and glia after transplantation into the striatum of the adult rat striatum | |
Mummery et al. | Part A: Directed Differentiation of Human Embryonic Stem Cells into Cardiomyocytes | |
AU2004219990A1 (en) | Differentiation of human embryonic stem cells to cardiomyocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040622 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040922 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041210 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070410 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070425 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110518 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120518 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130518 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |